Literature DB >> 7889540

A universal antibody-derived targeting agent.

R A Spooner1, M P Deonarain, P Savage, A A Epenetos.   

Abstract

We report bacterial expression of a single-chain antibody (ScFv) reactive against the haptens 4-hydroxy-3 nitrophenylacetic acid (NP) and 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP) that is suitable for targeting to mammalian cells in vitro in a novel two-step targeting strategy. Hapten-derivatized primary antibodies of known specificity, bound to target cells, can capture the ScFv. Specificity resides in the interaction of the primary targeting antibody with the target and the interaction of the ScFv for NP/NIP, since the ScFv does not bind cells and nonderivatized antibodies bound at cells cannot capture the ScFv. The ScFv described here can therefore be considered as a universal agent for delivery of drugs, toxins, or radionuclides to any cell type for which a previously characterized antibody exists.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7889540     DOI: 10.1007/bf03033875

Source DB:  PubMed          Journal:  Cell Biophys        ISSN: 0163-4992


  25 in total

Review 1.  Biosynthetic antibody binding sites: development of a single-chain Fv model based on antidinitrophenol IgA myeloma MOPC 315.

Authors:  J E McCartney; L Lederman; E A Drier; N A Cabral-Denison; G M Wu; R S Batorsky; J S Huston; H Oppermann
Journal:  J Protein Chem       Date:  1991-12

2.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

3.  Expression and secretion of aequorin as a chimeric antibody by means of a mammalian expression vector.

Authors:  J Casadei; M J Powell; J H Kenten
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

4.  A comparison of strategies to stabilize immunoglobulin Fv-fragments.

Authors:  R Glockshuber; M Malia; I Pfitzinger; A Plückthun
Journal:  Biochemistry       Date:  1990-02-13       Impact factor: 3.162

5.  Immunogenicity of a free synthetic peptide: carrier-conjugation enhances antibody affinity for the native protein.

Authors:  M Mariani; L Bracci; R Presentini; D Nucci; P Neri; G Antoni
Journal:  Mol Immunol       Date:  1987-03       Impact factor: 4.407

6.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli.

Authors:  P Pack; A Plückthun
Journal:  Biochemistry       Date:  1992-02-18       Impact factor: 3.162

8.  A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.

Authors:  V K Chaudhary; C Queen; R P Junghans; T A Waldmann; D J FitzGerald; I Pastan
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

9.  Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

Authors:  P D Senter; M G Saulnier; G J Schreiber; D L Hirschberg; J P Brown; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  A cytotoxic agent can be generated selectively at cancer sites.

Authors:  K D Bagshawe; C J Springer; F Searle; P Antoniw; S K Sharma; R G Melton; R F Sherwood
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.